TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06276140

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory analyses for the detection of iron deficiency anaemia
Description: Erythrocyte indices based on the preoperative complete blood count results will be calculated for each patient one day prior to surgical treatment.~Overall morbidity of each patient during hospital stay will be scored using the Comprehensive Complication Index (CCI). Intraoperative complications will be graded according to the ClassIntra classification of intraoperative adverse events. The quality of postoperative recovery of each observed patient will be scored on the first, second and fifth postoperative day, using the 15-item quality of recovery scale (QoR-15).~Data about red blood cell transfusion rate, all-cause infection rate, number of days when antibiotics were administered and the number of different antibiotics administered during hospital-stay will be collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory analyses for the detection of iron deficiency anaemia
Description: Erythrocyte indices based on the preoperative complete blood count results will be calculated for each patient one day prior to surgical treatment.~Overall morbidity of each patient during hospital stay will be scored using the Comprehensive Complication Index (CCI). Intraoperative complications will be graded according to the ClassIntra classification of intraoperative adverse events. The quality of postoperative recovery of each observed patient will be scored on the first, second and fifth postoperative day, using the 15-item quality of recovery scale (QoR-15).~Data about red blood cell transfusion rate, all-cause infection rate, number of days when antibiotics were administered and the number of different antibiotics administered during hospital-stay will be collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory analyses for the detection of iron deficiency anaemia
Description: Erythrocyte indices based on the preoperative complete blood count results will be calculated for each patient one day prior to surgical treatment.~Overall morbidity of each patient during hospital stay will be scored using the Comprehensive Complication Index (CCI). Intraoperative complications will be graded according to the ClassIntra classification of intraoperative adverse events. The quality of postoperative recovery of each observed patient will be scored on the first, second and fifth postoperative day, using the 15-item quality of recovery scale (QoR-15).~Data about red blood cell transfusion rate, all-cause infection rate, number of days when antibiotics were administered and the number of different antibiotics administered during hospital-stay will be collected.
Study: NCT05649488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus
Description: Introduction: After the preparation, release the intracoronary lithotripsy balloon catheter to the area to be treated and release the shock wave pulse for treatment. After the balloon reaches the predetermined position, use angiography to lock the position and fill the balloon to 6 atm. After the shock wave pulse therapy, the balloon was expanded to 8 atm according to the balloon compliance table and lasted for 10s. After the treatment, unload the balloon pressure, wait for the blood flow to recover, and repeat the second treatment after an interval of one minute, two cycles, releasing a total of 20 shock wave pulses as a treatment cycle.~Therapeutic apparatus specification: IVL-HVG-C01； Specifications of balloon catheter: C20012, C20015, C22512, C22515, C25012, C25015, C27512, C27515, C30012, C30015, C32512, C32515, C35012, C35015, C37512, C37515, C40012, C40015

Intervention type: DEVICE
Group type: OTHER
Intervention: Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus
Description: Introduction: After the preparation, release the intracoronary lithotripsy balloon catheter to the area to be treated and release the shock wave pulse for treatment. After the balloon reaches the predetermined position, use angiography to lock the position and fill the balloon to 6 atm. After the shock wave pulse therapy, the balloon was expanded to 8 atm according to the balloon compliance table and lasted for 10s. After the treatment, unload the balloon pressure, wait for the blood flow to recover, and repeat the second treatment after an interval of one minute, two cycles, releasing a total of 20 shock wave pulses as a treatment cycle.~Therapeutic apparatus specification: IVL-HVG-C01； Specifications of balloon catheter: C20012, C20015, C22512, C22515, C25012, C25015, C27512, C27515, C30012, C30015, C32512, C32515, C35012, C35015, C37512, C37515, C40012, C40015

Intervention type: DEVICE
Group type: OTHER
Intervention: Dragonfly Opstar Imaging Catheter
Description: OCT (optical coherence tomography) measurement using Dragonfly Opstar Imaging Catheter was performed in the OCT subgroup before or after the treatment of intracoronary lithotripsy balloon catheter and intracoronary lithotripsy therapeutic instrument, or after stent placement.
Study: NCT05489029

Intervention type: OTHER
Intervention: visual analog scale
Description: Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.

Intervention type: OTHER
Intervention: visual analog scale
Description: Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
Study: NCT06275815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit Together and Read (STAR)
Description: Sit Together and Read (STAR) features an explicit, systematic sequence of 15 objectives that target four dimensions of print knowledge: print organization, print meaning, letters, and words. These objectives are explicitly targeted in the context of repeated adult-child shared reading sessions and are systematically cycled over an intervention period so the child has repeated opportunities for acquiring the targeted print objectives. STAR is a manualized 15-week intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit Together and Read (STAR)
Description: Sit Together and Read (STAR) features an explicit, systematic sequence of 15 objectives that target four dimensions of print knowledge: print organization, print meaning, letters, and words. These objectives are explicitly targeted in the context of repeated adult-child shared reading sessions and are systematically cycled over an intervention period so the child has repeated opportunities for acquiring the targeted print objectives. STAR is a manualized 15-week intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit Together and Read (STAR)
Description: Sit Together and Read (STAR) features an explicit, systematic sequence of 15 objectives that target four dimensions of print knowledge: print organization, print meaning, letters, and words. These objectives are explicitly targeted in the context of repeated adult-child shared reading sessions and are systematically cycled over an intervention period so the child has repeated opportunities for acquiring the targeted print objectives. STAR is a manualized 15-week intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary Reward
Description: Caregiver receives a monetary reward of $0.50 for each session logged (up to 60 sessions) and audio-recording completed (up to 15 audio recordings).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Encouragement
Description: Caregiver receives three tailored encouraging text messages specific to each week of the Sit Together and Read intervention.
Study: NCT06126822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zabdeno® booster
Description: A single Zabdeno® booster vaccination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zabdeno® booster
Description: A single Zabdeno® booster vaccination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ervebo® booster
Description: A single Ervebo® booster vaccination
Study: NCT05616390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg IV d1,Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5mg/kg IV d1,Q3W

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Liver Protective Support Therapy
Description: Medical treatment such as liver protection therapy, antiviral therapy, platelet and granulocyte upgrading therapy
Study: NCT05013060

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics and microcapsulated sodium butyrate
Description: The patients who give their consent to take part in this study, will receive an oral microencapsulated sodium butyrate and a mixture of probiotics formulation 2 times a day for a period of 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: The patients who give their consent to take part in this study will receive an oral maltodextrin as placebo 2 times a day for a period of 12 weeks.
Study: NCT05574816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phi-Bra prototype measurements
Description: The bra prototype will be placed on the patient's breast. The patient will stay in a half-lying position during 15 min, the time duration of the measurements. Measurements will not be painful.~Measurements will only be realized one time during the first and unique visit of the patient.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phi-Bra prototype measurements
Description: The bra prototype will be placed on the patient's breast. The patient will stay in a half-lying position during 15 min, the time duration of the measurements. Measurements will not be painful.~Measurements will only be realized one time during the first and unique visit of the patient.
Study: NCT06689501

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The matching placebo is microcrystalline cellulose in the format of hard vegetable green capsules. Participants will consume a total of 4 capsules a day split in two servings.
Study: NCT04102891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microbiota modulation diet
Description: The Collect\&Go shopping carts of the 400 participants will be adapted by replacing food products by healthier alternative ones based on the Flemish food-based dietary guidelines and the microbiota modulation diet guidelines for the control and study arm respectively. Based on these guidelines, and the habitual dietary pattern and level of food literacy of the participant, personalized dietary advice will be provided. A dietitian helpline will be available for further nutritional issues as well.
Study: NCT06377098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil 50 mg Oral Tablet
Description: Sildenafil 50 mg given orally every eight hours up to three times while mother is in labor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo table given orally every eight hours up to three times while mother is in labor
Study: NCT04696835

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: speech audiometry
Description: 65dB, 55dB or 75dB SPL speech audiometry

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: speech audiometry
Description: 65dB, 55dB or 75dB SPL speech audiometry
Study: NCT06689969

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional implant placement method
Description: Site marking was the first step in preparing the place for implantation. Subsequently, using a high speed surgical handpiece and a surgical motor, a pilot drill was revolved at 1200 RPM in a clockwise rotation to the desired depth, creating a 1.5 mm first pilot osteotomy. An X-ray was obtained using paralleling pins to validate the angle between the surrounding teeth and the implants. Eventually the implant's precise placement was established. To prepare the osteotomy site to the desired diameter, drills are used sequentially at 1200 RPM in a clockwise motion. Gradually bigger drill diameters were used for incremental drilling. Based on the diameter of the desired implant, bur sizes were utilized in ascending order
Study: NCT06126822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ervebo® booster
Description: A single Ervebo® booster vaccination
Study: NCT04814485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1020+albumin-bound paclitaxel
Description: SHR-1020 combined with albumin-bound paclitaxel for advanced pancreatic cancer
Study: NCT05021614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valveclip® Transcatheter mitral valve repair
Description: Transcatheter mitral valve repair system
Study: NCT06212440

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Identification rate of sentinel lymph node for each dual method
Description: Direct comparison of identification rate between A arm and B arm, A arm and C arm.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Identification rate of sentinel lymph node for each dual method
Description: Direct comparison of identification rate between A arm and B arm, A arm and C arm.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Identification rate of sentinel lymph node for each dual method
Description: Direct comparison of identification rate between A arm and B arm, A arm and C arm.
Study: NCT06636864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Description: The patient was asked to lie on the side, the needle insertion point was located under the guidance of color ultrasound, and after local anesthesia, the needle was inserted into the subarachnoid space at the puncture point and morphine was injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal saline injection
Description: After the patient was asked to lie on his side, the injection point was determined under the guidance of color ultrasound. After local anesthesia, the needle was injected into the subarachnoid space and then normal saline was injected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAPB
Description: The patient was in a supine position. The rectus muscle was confirmed to be warping under the guidance of color photography, and the needle was injected with bupivacaine liposomes
Study: NCT06151015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice plus calorie-restricted diet
Description: One daily bottle (70ml) of nitrate-rich beetroot juice with a calorie-restricted diet (1,000kcal deficit).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate-rich beetroot juice plus weight-maintenance diet
Description: One daily bottle (70ml) of nitrate-rich beetroot juice with a weight-maintenance diet (energy will be met).
Study: NCT06636864

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAPB
Description: The patient was in a supine position. The rectus muscle was confirmed to be warping under the guidance of color photography, and the needle was injected with bupivacaine liposomes
Study: NCT05166811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate, Heptahydrate
Description: A single dose of intravenous magnesium sulfate given over 20 minutes through a peripheral intravenous line. Two arms of the study will deliver intravenous magnesium, one at a dose of 50 mg/kg, and the other at a dose of 75 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate, Heptahydrate
Description: A single dose of intravenous magnesium sulfate given over 20 minutes through a peripheral intravenous line. Two arms of the study will deliver intravenous magnesium, one at a dose of 50 mg/kg, and the other at a dose of 75 mg/kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: A single dose of intravenous 0.9% sodium chloride given over 20 minutes through a peripheral intravenous line as the placebo arm of the study.
Study: NCT06084104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008
Description: A single oral dose of 200mg DZD9008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008
Description: A single oral dose of 200mg DZD9008
Study: NCT06129760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apple Watch
Description: The wearable sensor device is the Apple Watch Series 6 or newer
Study: NCT05771194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine preoperative and postoperative anti-infection therapy
Description: received gatifloxacin eye drops (Otsuka Pharmaceutical Co., Ltd.) 4 times daily and gatifloxacin eye ointment once every night (Shenyang Xing Qi Pharmaceutical Co., Ltd) for 3 days before surgery. Postoperatively, gatifloxacin eye drops were administered 4 times daily, 0.1% fluorometholone (San Tian Pharmaceutical Co., Ltd., China) was administered 4 times daily, and pranoprofen (Qian Su Pharmaceutical Co., Ltd., Japan) was administered 4 times daily. The doses of the above three drugs were reduced each week. The compound tropicamide was administered once a day (Shentian Pharmaceutical Co., Ltd., China). All of the above procedures were stopped 1 month after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine preoperative and postoperative anti-infection therapy
Description: received gatifloxacin eye drops (Otsuka Pharmaceutical Co., Ltd.) 4 times daily and gatifloxacin eye ointment once every night (Shenyang Xing Qi Pharmaceutical Co., Ltd) for 3 days before surgery. Postoperatively, gatifloxacin eye drops were administered 4 times daily, 0.1% fluorometholone (San Tian Pharmaceutical Co., Ltd., China) was administered 4 times daily, and pranoprofen (Qian Su Pharmaceutical Co., Ltd., Japan) was administered 4 times daily. The doses of the above three drugs were reduced each week. The compound tropicamide was administered once a day (Shentian Pharmaceutical Co., Ltd., China). All of the above procedures were stopped 1 month after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artificial tear therapy
Description: given 0.1% sodium hyaluronate eye drops 4 times daily for 3 days before surgery (Jiang Xi, Zhen Shiming Pharmaceutical Co., Ltd.) and 3 months after surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cleaning, hot compresses and massage of the meibomian gland
Description: Group B used a steam eye mask (Your Ga Run Fang, Shang Hai Run Mu Industrial Co., Ltd.) for 20 minutes 3 days before surgery. Sterile cotton swabs were used to apply physiological saline to the eyelid for local cleaning, and the secretions and phosphorus debris on the surface of the eyelid margin were removed to fully expose the meibomian gland. Meibomian gland tweezers were used to squeeze from the root of the gland toward the opening to expel the secretions; each gland was expressed twice. After the operation, an appropriate amount of gatifloxacin cream (Shen Yang Xing Qi Pharmaceutical Co., Ltd.) was applied to the conjunctival sac to prevent infection. Hot towels (40°C) were applied to the eyes for 10 minutes every morning and evening for 3 days before the operation.
Study: NCT06689969

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osseodensification to implant placement using densah bur kit
Description: Beginning with site marking, the area was prepared for implantation. A high speed surgical handpiece and a surgical motor (surgic pro® NSK, Japan) were then used to construct a 1.5 mm initial pilot osteotomy using a pilot drill spun at 1200 RPM in a clockwise rotation to the desired depth. In order to verify the angle between the surrounding teeth and the implants, paralleling pins were used to capture an X-ray.~After it was determined that the implant was in the proper location, OD was used to extend the osteotomy using a Densah® Bur VT1525 2.0-mm (VersahTM, LLC, USA) in non-cutting anticlockwise rotation at 1200 RPM (Densifying Mode). The osteotomy was expanded to the desired diameter by repeatedly using a DensahTM Bur operating in a non-cutting anticlockwise (CCW) direction at 1200 RPM (Densifying Mode). Gradually increasing drill diameters were used for incremental drilling. Based on the diameter of the desired implant, bur sizes (diameters) were utilised in ascending order
Study: NCT05274347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muti-faceted virtual, remote intervention
Description: Patients will be provided with tablets with internet connectivity and Aetonix software, along with a blood pressure cuff, weigh scale and pulse oximeter with blue tooth capability. These will be used to deliver virtual CBT sessions as well as remote monitoring of vital signs, symptoms and enhanced communication. The intervention duration will be 10 weeks.
Study: NCT06118775

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EaDyn Weaning Arm:
Description: The norepinephrine dose will be gradually tapered, decreasing by 0.02 mcg/kg/min every 30 minutes. In the experimental group, vasopressor weaning is guided by the EaDyn value. Weaning can proceed as long as the EaDyn remains at or above 0.90. However, if the value drops below 0.90, the weaning process halts, and the norepinephrine dose is reverted to the last dose where the EaDyn value was ≥ 0.90. Regardless of the EaDyn value, any patient experiencing a MAP decline below 50 mmHg will be withdrawn from the study. Should the MAP range between 50 mmHg and 69 mmHg, a fluid challenge of 250 mL of isotonic crystalloid must be administered before weaning continues.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PAM Weaning Arm:
Description: The norepinephrine dose will be gradually tapered, decreasing by 0.02 mcg/kg/min every 30 minutes. In the control group, vasopressor weaning progresses as long as the MAP remains at or above 70 mmHg. If the MAP falls between 50 and 69 mmHg, preload dependency is reassessed. Upon confirmation, a new fluid challenge is administered; vasopressor weaning halts, and the vasopressor dose reverts to its prior value. The weaning process can continue as long as the patient's MAP remains above 50 mmHg. If the MAP drops below this threshold, the patient exits the study.
Study: NCT05447962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-to-Clinic Linkage Implementation Program in Barbershops (CLIP)
Description: Multilevel intervention designed to mitigate adverse social determinants of health (SDoH) via linkage to care, health system navigation, and referral to social services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community-to-Clinic Linkage Implementation Program in Barbershops (CLIP)
Description: Multilevel intervention designed to mitigate adverse social determinants of health (SDoH) via linkage to care, health system navigation, and referral to social services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Barbershop-Based Facilitation (BF)
Description: Trained and qualified facilitators assist community health workers (CHWs) to: 1) increase their confidence in delivering CLIP; 2) understand participants' concerns and beliefs about hypertension (HTN); and 3) develop skills in lifestyle counseling to help the men initiate lifestyle modification.